Proxima (formerly VantAI), the AI-native biotech company pioneering the next generation of AI-driven drug discovery for proximity therapeutics, has announced an oversubscribed $80 million seed financing. The round was led by DCVC, with participation from NVentures (NVIDIA's venture capital arm), Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic Ventures, Alexandria Venture Investments, Modi Ventures, and additional strategic and institutional investors.

Proxima is pioneering a transformative approach to drug discovery by illuminating the dynamic networks of protein interactions that drive biological function. Leveraging a groundbreaking structural proteomics platform and frontier machine learning capabilities, Proxima is uniquely positioned to unlock novel therapeutic strategies that induce, modulate, or block protein interfaces, making previously undruggable targets accessible and providing powerful new ways to target diseases by rewiring cellular circuitry. Alongside a robust and mechanistically differentiated internal pipeline, Proxima collaborates extensively with external partners to accelerate the discovery and development of innovative therapies across novel proximity modalities.